Deutsche Bank initiated coverage of Neurocrine (NBIX) with a Hold rating and $138 price target
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NBIX:
- Neurocrine management to meet with Oppenheimer
- Neurocrine price target lowered to $163 from $165 at Guggenheim
- Neurocrine Biosciences’ Earnings Call: Record Sales & Strategic Growth
- Neurocrine price target lowered to $148 from $154 at RBC Capital
- Neurocrine price target lowered to $147 from $157 at Wedbush
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue